Cynvenio Biosystems to Present Clinical Data on Mutational Analysis of LiquidBiopsy® Tumor Samples at the 2013 ASCO Annual Meeting

Company demonstrates feasibility of blood-to-mutation genomic analysis of CTCs for Breast Cancer and Prostate Cancer patients

Westlake Village, Calif., May 24, 2013 – Cynvenio Biosystems, Inc., a cancer diagnostics company focused on the molecular analysis of tumor biomarkers derived from whole blood, today announced that clinical data from two research collaborations in breast and prostate cancer will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2013 taking place May 31-June 4, 2013 in Chicago. These data highlight the company’s progress in the molecular analysis of circulating tumor cells (CTC) by next generation sequencing.

The breast cancer study was completed with Fox Chase Cancer Center and the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia, Pennsylvania. The prostate cancer study was completed in collaboration with the Norris Comprehensive Cancer Center at the University of Southern California in Los Angeles.

Both studies demonstrate the feasibility of sequencing CTC populations isolated by LiquidBiopsy to discover disease-associated mutations. The potential of this approach is to monitor patients frequently over their entire cancer care cycle to determine the most appropriate treatment, measure response to therapy and, ultimately, screen the population for disease via a simple blood draw.

“These two studies further demonstrate the importance of applying new technology to the  molecular analysis of cancer,” said André de Fusco, president and CEO of Cynvenio Biosystems, Inc. “In oncology, as in all fields, better decisions are based on frequent analysis of the most up-to-date information - not less - and our goal is to place this capability within reach of every doctor and patient”.

The schedule for poster presentations by Cynvenio Biosystems and its collaborators is:

Time and Date: 1:15-5:00 p.m. Saturday, June 1
Title: Classifying circulating mutation bearing tumor cells from breast cancer patients
Abstract Number:  115791
Poster Board Number: 6C
Session: General Poster Session: Breast Cancer 
Type: Poster Session
Location: South Hall 2A
Presenters: William Strauss*, Paul W. Dempsey*, Jessamine Winer-Jones*, Catherine Bingham†, R. Katherine Alpaugh†, Massimo Cristofanilli‡; *Cynvenio Biosystems, Inc., Westlake Village, CA; †Fox Chase Cancer Center, Philadelphia, PA; ‡Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA. 

Time and Date: 1:15-5:00 p.m. Monday, June 3
Title: Targeted Next Generation Sequencing (NGS) of Circulating Tumor Cells (CTCs) in Hormone-Sensitive Prostate Cancer
Abstract: 11040
Poster Board Number: 43C
Session: General Poster Session: Genitourinary Cancer, Prostate Cancer
Location: South Hall 2A
Presenters: Stephen Liu†, Paul Dempsey*, William Strauss*, Yucheng Xu†, Tong Xu†, Jacek Pinski†, Tanya Dorff†, David Quinn†, André de Fusco*, Tim Triche†, Janine McMurdie, Amir Goldkorn†; *Cynvenio Biosystems, Inc., Westlake Village, CA; Life Technologies, Inc., Carlsbad, CA.; †University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA.

About Cynvenio Biosystems, Inc.

Cynvenio Biosystems, Inc. is a molecular diagnostics company dedicated to the early detection and targeted treatment of cancer. Cynvenio has developed and deployed the LiquidBiopsy® system to enable realtime monitoring of tumor cell-associated mutations from a simple blood draw. This information can be used by physicians, academic centers, and drug developers to define treatment cycles for individual patients, efficiently select patients for drug trials and monitor patient response at any stage of disease.

Cynvenio’s CLIA service lab is based in Westlake Village, California. To find out more about the company please visit:  www.cynvenio.com and www.liquidbiopsy.com.
 

LiquidBiopsy is a registered trademark of Cynvenio Biosystems, Inc.